Hydroxy/Hydroperoxy/Epoxy/Oxo Eicosanoids
Products Related to Hydroxy/Hydroperoxy/Epoxy/Oxo Eicosanoids(138)
- GC20027(±)5(6)-DiHET MaxSpec® StandardCAS: 213382-49-1Purity: >95.00%
5(6)-DiHET is a fully racemic version of the enantiomeric forms biosynthesized from 5(6)-EET by epoxide hydrolases.
- GC40268(±)14(15)-DiHETPurity: >98.00%
Epoxide hydrolases convert the EETs into vicinal diols, with the concurrent loss of much of their biological activity.
- GC40271(±)5(6)-DiHET MaxSpec® StandardCAS: 213382-49-1Purity: >95.00%
5(6)-DiHET is a fully racemic version of the enantiomeric forms biosynthesized from 5(6)-EET by epoxide hydrolases.
- GC40272(±)8(9)-DiHETCAS: 192461-96-4Purity: >98.00%
Epoxide hydrolases convert the EETs into vicinal diols, with the concurrent loss of much of their biological activity.
- GC40279(±)11(12)-DiHETPurity: >98.00%
Epoxide hydrolases convert the EETs into vicinal diols, with the concurrent loss of much of their biological activity.
- GC40339Hepoxilin A3 methyl esterPurity: >98.00%
Hepoxilin A3 (HxA3) methyl ester is an ester version of HxA3 that more potently induces calcium release from intracellular stores and then induces calcium influx in suspended human neutrophils.
- GC4034912(S)-HETE-19,20-alkynePurity: >97.00%
12(S)-HETE is the predominant lipoxygenase product of mammalian platelets.
- GC40359(±)12-HEPECAS: 81187-21-5Purity: >98.00%
(±)12-HEPE is produced by non-enzymatic oxidation of EPA.
- GC40360(±)14(15)-EpETECAS: 131339-24-7Purity: >90.00%
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators.
- GC40361(±)15-HEPECAS: 88852-33-9Purity: >98.00%
(±)15-HEPE is produced by non-enzymatic oxidation of EPA.
- GC40362(±)18-HEPECAS: 141110-17-0Purity: >95.00%
(±)18-HEPE is produced by non-enzymatic oxidation of EPA.
- GC40363(±)5(6)-DiHETE lactonePurity: >90.00%
Eicosapentaenoic acid is metabolized, in part, through cytochrome P450-catalyzed epoxidation followed by conversion to the vicinal diols by epoxide hydrolases.
- GC40365(±)8(9)-EpETECAS: 851378-93-3Purity: >95.00%
Eicosapentaenoic acid is converted to epoxyeicosatetraenoic acids (EpETEs) by several cytochrome P450 isoforms.
- GC4036811(R)-HEPECAS: 109430-11-7Purity: >98.00%
11(R)-HEPE is produced by the oxidation of EPA by 11(R)-LO.
- GC4036911(S)-HEPECAS: 156473-26-6Purity: >98.00%
11(S)-HEPE is a monohydroxy fatty acid derived from EPA, theoretically by the action of COX.
- GC4037012(R)-HEPECAS: 109430-12-8Purity: >98.00%
12(R)-HEPE is a monohydroxy fatty acid synthesized from EPA by the eggs of the sea urchin, S.
- GC4037112(S)-HEPECAS: 116180-17-7Purity: >98.00%
12(S)-HEPE is a monohydroxy fatty acid synthesized from EPA by the action of 12-LO.
- GC4037315(S)-HEPECAS: 86282-92-0Purity: >98.00%
15(S)-HEPE is a monohydroxy fatty acid synthesized from EPA by the action of 15-LO.
- GC4037415(S)-HEPE MaxSpec® StandardCAS: 86282-92-0Purity: >95.00%
15(S)-HEPE is a monohydroxy fatty acid synthesized from EPA by the action of 15-LO.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC20027 | (±)5(6)-DiHET MaxSpec® Standard | 213382-49-1 | >95.00% | |
5(6)-DiHET is a fully racemic version of the enantiomeric forms biosynthesized from 5(6)-EET by epoxide hydrolases. | ||||
| GC40268 | (±)14(15)-DiHET | - | >98.00% | |
Epoxide hydrolases convert the EETs into vicinal diols, with the concurrent loss of much of their biological activity. | ||||
| GC40271 | (±)5(6)-DiHET MaxSpec® Standard | 213382-49-1 | >95.00% | |
5(6)-DiHET is a fully racemic version of the enantiomeric forms biosynthesized from 5(6)-EET by epoxide hydrolases. | ||||
| GC40272 | (±)8(9)-DiHET | 192461-96-4 | >98.00% | |
Epoxide hydrolases convert the EETs into vicinal diols, with the concurrent loss of much of their biological activity. | ||||
| GC40279 | (±)11(12)-DiHET | - | >98.00% | |
Epoxide hydrolases convert the EETs into vicinal diols, with the concurrent loss of much of their biological activity. | ||||
| GC40339 | Hepoxilin A3 methyl ester | - | >98.00% | |
Hepoxilin A3 (HxA3) methyl ester is an ester version of HxA3 that more potently induces calcium release from intracellular stores and then induces calcium influx in suspended human neutrophils. | ||||
| GC40349 | 12(S)-HETE-19,20-alkyne | - | >97.00% | |
12(S)-HETE is the predominant lipoxygenase product of mammalian platelets. | ||||
| GC40359 | (±)12-HEPE | 81187-21-5 | >98.00% | |
(±)12-HEPE is produced by non-enzymatic oxidation of EPA. | ||||
| GC40360 | (±)14(15)-EpETE | 131339-24-7 | >90.00% | |
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators. | ||||
| GC40361 | (±)15-HEPE | 88852-33-9 | >98.00% | |
(±)15-HEPE is produced by non-enzymatic oxidation of EPA. | ||||
| GC40362 | (±)18-HEPE | 141110-17-0 | >95.00% | |
(±)18-HEPE is produced by non-enzymatic oxidation of EPA. | ||||
| GC40363 | (±)5(6)-DiHETE lactone | - | >90.00% | |
Eicosapentaenoic acid is metabolized, in part, through cytochrome P450-catalyzed epoxidation followed by conversion to the vicinal diols by epoxide hydrolases. | ||||
| GC40364 | (±)5-HEPE | 83952-40-3 | >97.00% | |
(±)5-HEPE is produced by non-enzymatic oxidation of EPA. | ||||
| GC40365 | (±)8(9)-EpETE | 851378-93-3 | >95.00% | |
Eicosapentaenoic acid is converted to epoxyeicosatetraenoic acids (EpETEs) by several cytochrome P450 isoforms. | ||||
| GC40366 | (±)8-HEPE | 99217-77-3 | >98.00% | |
(±)8-HEPE is produced by non-enzymatic oxidation of EPA. | ||||
| GC40367 | (±)9-HEPE | 286390-03-2 | >98.00% | |
(±)9-HEPE is produced by non-enzymatic oxidation of EPA. | ||||
| GC40368 | 11(R)-HEPE | 109430-11-7 | >98.00% | |
11(R)-HEPE is produced by the oxidation of EPA by 11(R)-LO. | ||||
| GC40369 | 11(S)-HEPE | 156473-26-6 | >98.00% | |
11(S)-HEPE is a monohydroxy fatty acid derived from EPA, theoretically by the action of COX. | ||||
| GC40370 | 12(R)-HEPE | 109430-12-8 | >98.00% | |
12(R)-HEPE is a monohydroxy fatty acid synthesized from EPA by the eggs of the sea urchin, S. | ||||
| GC40371 | 12(S)-HEPE | 116180-17-7 | >98.00% | |
12(S)-HEPE is a monohydroxy fatty acid synthesized from EPA by the action of 12-LO. | ||||
| GC40372 | 12-OxoETE | 108437-64-5 | >90.00% | |
12-OxoETE is synthesized by human platelets and Aplysia nervous tissue after incubation with arachidonic acid. | ||||
| GC40373 | 15(S)-HEPE | 86282-92-0 | >98.00% | |
15(S)-HEPE is a monohydroxy fatty acid synthesized from EPA by the action of 15-LO. | ||||
| GC40374 | 15(S)-HEPE MaxSpec® Standard | 86282-92-0 | >95.00% | |
15(S)-HEPE is a monohydroxy fatty acid synthesized from EPA by the action of 15-LO. | ||||
| GC40376 | 15-OxoETE | 81416-72-0 | >98.00% | |
15-OxoETE is produced by oxidation of the 15-hydroxyl of 15-HETE. | ||||
